Roles of T Cells in Immunotherapy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 5621
Special Issue Editors
Interests: AI-driven drug discovery; pharmaceutical biotechnology; pharmacogenomics; neoantigens; computational biology
Special Issue Information
Dear Colleagues,
Tumor immunotherapies have achieved important success, but they still have some problems, such as low effective rate and unclear effectiveness. As important effector cells of human immunity, T cells are directly or indirectly involved in tumor immunotherapies. Therefore, in-depth analysis of the roles of T cells in different immunotherapies is an effective way to improve their clinical efficacy. In this Special Issue, we welcome the submission of original research papers and reviews on the roles of T cells in immunotherapy. Relevant topics of interest to this Special Issue include (but are not limited to):
- Recognition of T-cell epitopes or tumor neoantigens;
- Design of tumor vaccines;
- T-cell antigen recognition;
- Design of TCR-based immunotherapies;
- Regulation of T-cell activities.
Dr. Zhan Zhou
Dr. Wenbin Zhao
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor immunotherapies
- T-cell engagers
- adoptive T-cell therapy
- immune checkpoint inhibitors
- tumor vaccines
- costimulatory signal
- T-cell receptors
- neoantigens